On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab. For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.
On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab.
For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.
Posted on 11/14/2025
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
